Literature DB >> 28161700

Clinical Features and Outcomes of a Racially Diverse Population with Fibrillary Glomerulonephritis.

Fernanda Payan Schober1, Meghan A Jobson, Caroline J Poulton, Harsharan K Singh, Volker Nickeleit, Ronald J Falk, J Charles Jennette, Patrick H Nachman, William F Pendergraft Iii.   

Abstract

BACKGROUND: Fibrillary glomerulonephritis is characterized by randomly arranged fibrils, approximately 20 nm in diameter by electron microscopy. Patients present with proteinuria, hematuria and kidney insufficiency, and about half of the reported patients progress to end-stage kidney disease within 4 years. The dependence of patient characteristics and outcomes on race has not been explored. In this study, we describe a cohort of patients with fibrillary glomerulonephritis and compare their clinical characteristics and outcomes with those of patients previously described.
METHODS: The University of North Carolina (UNC) Nephropathology Database was used to retrospectively identify patients diagnosed with fibrillary glomerulonephritis between 1985 and 2015. Of these patients, those treated at UNC were selected. Their demographic and clinical characteristics - including signs and symptoms, comorbidities, laboratory values, treatments and outcomes - were compared with those of patients described earlier.
RESULTS: Among the 287 patients identified, 42 were treated at the UNC Kidney Center. When compared to earlier cohorts, a higher frequency of black race, hepatitis C virus (HCV) infection and use of hemodialysis were noted in both black and HCV-positive patients. Autoimmune diseases, infections and malignancies were frequently observed, present in over half of all cases.
CONCLUSION: According to this study, fibrillary glomerulonephritis represents a secondary glomerular disease process (associated with autoimmune disease, infection or malignancy) in many cases and hence screening is essential. As the screening for comorbidities increased over time, more underlying causes were identified. We noted a high frequency of HCV among black patients, suggesting a possible causative association. Treatment of underlying disease is essential for patients for the best outcome.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2017        PMID: 28161700      PMCID: PMC5482172          DOI: 10.1159/000455390

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  28 in total

Review 1.  Hepatitis C virus infection in African Americans.

Authors:  Brian L Pearlman
Journal:  Clin Infect Dis       Date:  2005-11-29       Impact factor: 9.079

2.  Fibrillary glomerulonephritis occurring in association with hereditary angioneurotic oedema, pernicious anaemia and hypothyroidism.

Authors:  G Whitaker; E A Brown; J Moss; D Woodrow; A Frankel
Journal:  Nephrol Dial Transplant       Date:  1998-07       Impact factor: 5.992

3.  Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy.

Authors:  Sanjeev Sethi; Jason D Theis; Julie A Vrana; Fernando C Fervenza; Anjali Sethi; Qi Qian; Patrick Quint; Nelson Leung; Ahmet Dogan; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-14       Impact factor: 8.237

4.  Fibrillary glomerulonephritis in Castleman's disease.

Authors:  A Miadonna; C Salmaso; P Palazzi; A Elli; P Braidotti; G Lambertenghi Deliliers
Journal:  Leuk Lymphoma       Date:  1998-01

5.  Fibrillary glomerulonephritis: an entity with unusual immunofluorescence features.

Authors:  C E Alpers; H G Rennke; J Hopper; C G Biava
Journal:  Kidney Int       Date:  1987-03       Impact factor: 10.612

6.  End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases.

Authors:  Andrew Mallett; Wen Tang; Gareth Hart; Stephen P McDonald; Carmel M Hawley; Sunil V Badve; Neil Boudville; Fiona G Brown; Scott B Campbell; Philip A Clayton; David W Johnson
Journal:  Am J Nephrol       Date:  2015-09-30       Impact factor: 3.754

7.  Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy.

Authors:  A Fogo; N Qureshi; R G Horn
Journal:  Am J Kidney Dis       Date:  1993-09       Impact factor: 8.860

8.  Fibrillary glomerulonephritis associated with limited scleroderma: a case report.

Authors:  Georges N Nakhoul; James F Simon
Journal:  Clin Nephrol       Date:  2016-04       Impact factor: 0.975

9.  Long-term kidney disease outcomes in fibrillary glomerulonephritis: a case series of 27 patients.

Authors:  Vincent Javaugue; Alexandre Karras; François Glowacki; Brigitte McGregor; Corinne Lacombe; Jean-Michel Goujon; Stéphanie Ragot; Pierre Aucouturier; Guy Touchard; Frank Bridoux
Journal:  Am J Kidney Dis       Date:  2013-06-04       Impact factor: 8.860

10.  Fibrillary renal deposits and nephritis.

Authors:  J L Duffy; E Khurana; M Susin; G Gomez-Leon; J Churg
Journal:  Am J Pathol       Date:  1983-12       Impact factor: 4.307

View more
  6 in total

1.  Fibrillary Glomerulonephritis: Clinicopathologic Features and Atypical Cases from a Multi-Institutional Cohort.

Authors:  Nicole K Andeen; Megan L Troxell; Maziar Riazy; Rupali S Avasare; Jessica Lapasia; J Ashley Jefferson; Shreeram Akilesh; Behzad Najafian; Roberto F Nicosia; Charles E Alpers; Kelly D Smith
Journal:  Clin J Am Soc Nephrol       Date:  2019-11-04       Impact factor: 8.237

2.  Complete remission of DnaJ homolog subfamily B member 9-positive fibrillary glomerulonephritis following steroid monotherapy in an elderly Japanese woman.

Authors:  Takahiro Uchida; Shuuhei Komatsu; Takashi Sakai; Aki Kojima; Sachiko Iwama; Kentaro Sugisaki; Takashi Oda
Journal:  CEN Case Rep       Date:  2021-03-03

Review 3.  Fibrillary Glomerulonephritis and DnaJ Homolog Subfamily B Member 9 (DNAJB9).

Authors:  Nattawat Klomjit; Mariam Priya Alexander; Ladan Zand
Journal:  Kidney360       Date:  2020-07-08

4.  Rituximab and Fibrillary Glomerulonephritis: Interest of B Cell Reconstitution Monitoring.

Authors:  Claire Leibler; Anissa Moktefi; Marie Matignon; Céline Debiais-Delpech; Julie Oniszczuk; Dil Sahali; José L Cohen; Philippe Grimbert; Vincent Audard
Journal:  J Clin Med       Date:  2018-11-09       Impact factor: 4.241

5.  Characteristics of patients with coexisting DNAJB9-associated fibrillary glomerulonephritis and IgA nephropathy.

Authors:  Samar M Said; Alejandro Best Rocha; Anthony M Valeri; Mohamad Sandid; Anhisekh Sinha Ray; Mary E Fidler; Mariam Priya Alexander; Christopher P Larsen; Samih H Nasr
Journal:  Clin Kidney J       Date:  2020-12-05

6.  A Case of Fibrillary Glomerulonephritis.

Authors:  Maamannan Venkataraj; Phani P Morisetti
Journal:  Cureus       Date:  2022-08-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.